Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) Download "Poster presentation at the 2022 ASH meeting" PDF
Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma Download "Poster presentation at the 2022 ASH meeting" PDF
Combination of lemzoparlimab and HER2-ADC elicits enhanced activity against HER2 expressing tumors Download "Poster presentation at the 2022 SITC Meeting" PDF
Lemzoparlimab, a Novel Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results Download "Proffered paper presentation at the 2022 ESMO meeting" PDF
Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin’s Lymphoma: Initial Clinical Results Download "Poster presentation at the 2021 ASH meeting" PDF
A first-in-patient study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results Download "Poster presentation at the 2020 SITC Meeting" PDF
TJC4, A Differentiated RBC Sparing Anti-CD47 Antibody for Anti-Cancer Therapy Download "Poster presentation at the 2019 ASH meeting" PDF
A differentiated CD47 therapeutic antibody recognizing a novel epitope and sparing erythrocytes and platelets Download "Poster presentation at the 2017 EACR meeting" PDF
Uliledlimab and toripalimab combination therapy in treatment-naïve advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker Download "Poster presentation at the 2023 ASCO meeting" PDF
Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway Download "Poster presentation at the 2022 SITC Meeting" PDF
The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer Download "Poster presentation at the 2021 ASCO meeting" PDF
TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies Download "Poster presentation at the 2021 SITC meeting" PDF
Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation Download "Poster presentation at the 2020 AACR meeting" PDF
A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors Download "Poster presentation at the 2019 SITC meeting" PDF
Discovery of a novel Claudin6-4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation Download "Poster presentation at the 2022 AACR meeting" PDF
Inhibition of B7-H3 by Enoblituzumab Elicits Antitumor Immune Modulation in Both Innate and Adaptive Immunity Download "Poster presentation at the 2022 AACR meeting" PDF
A novel immunocytokine fusion protein combining tumor-targeting anti-CD47 antibody with GM-CSF cytokine for enhanced anti-tumor efficacy Download "Poster presentation at the 2018 AACR meeting" PDF
A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes Download "Poster presentation at the 2019 SITC meeting" PDF
